Takafumi Ochiai (Partner)’s comment was quoted in an article entitled "No Objection to the Classification of Drugs Requiring Supervision Not Shifting to OTC Use," in the Nikkei Medical, dated August 10, 2023.

Takafumi Ochiai (Partner)’s comment was quoted in an article entitled "No Objection to the Classification of Drugs Requiring Supervision Not Shifting to OTC Use," in the Nikkei Medical, dated August 10, 2023, published by Nikkei Inc.